Agena Bioscience's LungFUSION Panel

Agena Bioscience has released its LungFUSION Panel for rapid and sensitive identification of oncogenic ALK, RET, and ROS1 gene fusions in non-small cell lung cancer tumors. The panel contains built-in controls to simultaneously assess RNA quality, report DNA contamination, and determine the relative amount of lung tissue present in the sample. It runs on the firm's MassArray platform, which detects genetic variation directly by end-point PCR and label-free mass spectrometry.